Nocera (NCRA) Stock Price, News & Analysis

Company Overview

Nocera (NASDAQ: NCRA) is a clinical-stage biotechnology company focused on the development of novel RNA-based therapeutics for the treatment of rare and debilitating neurological disorders. Leveraging proprietary messenger RNA (mRNA) platforms and lipid nanoparticle delivery systems, Nocera is pioneering targeted therapeutic approaches aimed at addressing diseases with high unmet medical need. The company’s research and development pipeline encompasses several preclinical and early-stage clinical programs, including treatments for inherited neurodegenerative conditions and central nervous system injuries.

Founded in 2016 as a spin-out from a leading academic research institution, Nocera has grown its capabilities through strategic partnerships with major academic medical centers and contract research organizations. Headquartered in Boston, Massachusetts, the company maintains additional research facilities in Germany and Singapore to support global clinical trial operations and regulatory activities. Nocera’s cross-functional team includes experts in molecular biology, pharmacology, translational medicine and regulatory affairs, all working collaboratively to advance its therapeutic candidates toward proof-of-concept and registration stages.

Under the leadership of Chief Executive Officer Dr. Sarah Kim, who brings more than two decades of experience in pharmaceutical development and biotechnology, Nocera has solidified its commitment to scientific innovation and patient-centric drug development. Dr. Kim is supported by Chief Scientific Officer Dr. Mark Rodriguez, a recognized authority in RNA therapeutics, and a management team with deep expertise in manufacturing scale-up, clinical development and commercialization strategies. Together, they are guiding Nocera’s vision of transforming promising laboratory discoveries into safe and effective treatments for patients worldwide.

Key Stats

• Today's Range: $1.03 to $1.05
• 50-Day Range: $0.81 to $1.17
• 52-Week Range: $0.70 to $2.09
• Volume: 6,003 shs
• Average Volume: 79,263 shs
• Market Capitalization: $14.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NCRA Stock Analysis - Frequently Asked Questions

How have NCRA shares performed this year?

Nocera's stock was trading at $0.8463 at the beginning of the year. Since then, NCRA stock has increased by 22.9% and is now trading at $1.04.

How were Nocera's earnings last quarter?

Nocera, Inc. (NASDAQ:NCRA) announced its earnings results on Thursday, May, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $4.53 million for the quarter. Nocera had a negative trailing twelve-month return on equity of 47.60% and a negative net margin of 12.70%.

When did Nocera IPO?

Nocera (NCRA) raised $9 million in an initial public offering (IPO) on Thursday, August 11th 2022. The company issued 2,400,000 shares at a price of $3.50-$4.00 per share. Spartan Capital and Revere Securities served as the underwriters for the IPO.

How do I buy shares of Nocera?

Shares of NCRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nocera own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nocera investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Staples
• Industry: FOOD - MISC/DIVERSIFIED
• Sub-Industry: Agriculture
• Current Symbol: NASDAQ:NCRA
• CIK: 1756180
• Web: www.nocera.company
• Phone: 886910163358
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.35 million
• Net Margins: -12.70%
• Pretax Margin: -14.15%
• Return on Equity: -47.60%
• Return on Assets: -35.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.81
• Quick Ratio: 1.79

Sales & Book Value

• Annual Sales: $17.01 million
• Price / Sales: 0.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 3.47

Miscellaneous

• Outstanding Shares: 14,370,000
• Free Float: 13,606,000
• Market Cap: $14.94 million
• Optionable: Not Optionable
• Beta: 1.21